The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Spectranetics's revenues will expand 10.0% and EPS will grow from $0.00 per share the prior year.
The average estimate for revenue is $36.6 million. On the bottom line, the average EPS estimate is -$0.03.
Last quarter, Spectranetics logged revenue of $36.8 million. GAAP reported sales were 13% higher than the prior-year quarter's $32.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.03. GAAP EPS of $0.02 for Q4 were 100% higher than the prior-year quarter's $0.01 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 73.3%, 40 basis points better than the prior-year quarter. Operating margin was 3.4%, 230 basis points worse than the prior-year quarter. Net margin was 1.8%, 70 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $154.8 million. The average EPS estimate is $0.02.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 156 members out of 174 rating the stock outperform, and 18 members rating it underperform. Among 38 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give Spectranetics a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Spectranetics is buy, with an average price target of $15.93.
Is Spectranetics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Spectranetics to My Watchlist.